Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878571 | 0.92 | TRPV1 (0.42) | PIK3CAMTORTRPV1ACACBACACA | |
| SCHEMBL3879897 | 0.91 | TRPV1 (0.44) | PIK3CAMTORTRPV1PIK3CBPIK3CG | |
| SCHEMBL3887535 | 0.89 | TRPV1 (0.44) | PIK3CAMTORTRPV1 | |
| SCHEMBL3884304 | 0.89 | PIK3CA (0.41) | PIK3CAMTORPIK3CBPIK3CGKCNH2 | |
| SCHEMBL3878696 | 0.89 | ACACB (0.43) | PIK3CAMTORTRPV1PIK3CBPIK3CG | |
| SCHEMBL3883895 | 0.88 | PIK3CA (0.45) | PIK3CAMTORTRPV1PIK3CBPIK3CG | |
| SCHEMBL3879904 | 0.87 | TRPV1 (0.43) | PIK3CAMTORTRPV1PIK3CBPIK3CG | |
| SCHEMBL3888346 | 0.87 | PIK3CA (0.43) | PIK3CAMTORTRPV1PIK3CBPIK3CG | |
| SCHEMBL3888123 | 0.87 | PIK3CA (0.43) | PIK3CAMTORTRPV1PIK3CBPIK3CG | |
| SCHEMBL3879034 | 0.87 | CYP1A2 (0.51) | PIK3CAMTORTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | PIK3CA 1107/4885MTOR 2949/4885TRPV1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.